Wednesday, July 2, 2025 7/2/2025

Maternal Omics to Maximize Immunity

Award Number: U19AI167899
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/19/2022
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Maternal Omics to Maximize Immunity - Overall: Summary From the moment of fertilization to birth, the maternal immune system evolves, adapts, and supports the growth of a fetal allograft that ultimately perpetuates the human race. Immunological changes throughout a pregnancy play a key deterministic role in the success of the pregnancy. While pregnancy was historically regarded as a simple shift towards tolerance, emerging immunological data point to remarkable dynamic changes during pregnancy. The pregnancy immunome must protect the fetus from a maternal attack while at the same time it must afford the maternal-fetal dyad protection from invading pathogens. The health of the mother and the fetus requires that these two opposing immunological tasks work in concert. Thus collectively, pregnancy marks a whirlwind of immune adaptations that render the pregnant immune system a truly unique immunologic marvel. Despite our growing appreciation for these highly controlled dynamic shifts, the precise mechanisms that lead to optimal pregnancy health, profoundly impacting both mother and fetus, are incompletely understood, delaying the development of targeted therapies for this population. Capitalizing on this unique moment in vaccine history, with the introduction of several novel-vaccine platforms for SARS-CoV-2, the consortium will build a Pregnancy Immune Atlas via the application of high-density immunological profiling technologies to deeply and comprehensively dissect the overall changes that occur across pregnancy and how the immune system, as a collective, responds to in vivo perturbations with vaccines. Using both de novo vaccine induced immune responses and booster vaccination, the consortium will capture overall changes in the pregnant ImmunOME as well as shifts in the pregnant AdaptOME to fully capture the immunological mechanisms that govern the balanced growth of the fetus and battle of the maternal:fetal dyad against invading pathogens. Thus, together the Maternal ‘Omics to Maximize Immunity (MOMi) consortium seeks to build the foundational data to advance our knowledge of natural tolerance, fertility, shifts in immunity during pregnancy to better understand this evolutionary marvel required for the perpetuation of the human species.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,353,983 )
2025	2025	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	002	4	6/17/2025	NON-COMPETING CONTINUATION	$0
2025	2025	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	4	5/19/2025	NON-COMPETING CONTINUATION	$2,353,983
2025	2024	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	3	2/12/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,353,983

Issue Date FY: 2024 ( Subtotal = $2,953,983 )
2024	2024	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	3	3/19/2024	NON-COMPETING CONTINUATION	$2,353,983
2024	2024	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	002	3	8/29/2024	NON-COMPETING CONTINUATION	$0
2024	2024	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	3	8/14/2024	SUPPLEMENT FOR EXPANSION	$600,000
														Subtotal = $2,953,983

Issue Date FY: 2023 ( Subtotal = $2,353,983 )
2023	2023	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	003	2	4/4/2023	NON-COMPETING CONTINUATION	$0
2023	2023	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	2	3/30/2023	NON-COMPETING CONTINUATION	$2,353,983
2023	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	002	1	4/4/2023	NEW	$0
2023	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	2/13/2023	NEW	$0
														Subtotal = $2,353,983

Issue Date FY: 2022 ( Subtotal = $2,353,983 )
2022	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	1	8/8/2022	NEW	$0
2022	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	4/19/2022	NEW	$2,353,983
														Subtotal = $2,353,983

Grand Total All Awards = $10,015,932

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Maternal Omics to Maximize Immunity

Award Number: U19AI167899

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/19/2022

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer